- Home
- ARR vs VCEL Comparison
ARR vs VCEL Comparison
Compare ARR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARR | VCEL |
|---|---|---|
| Price | $17.10 | $37.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $18.50 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.7M | 517.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $13.98 | $28.95 |
| 52 Week High | $19.31 | $43.57 |
Technical Indicators
Market Signals| Indicator | ARR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 61.05 |
| Support Level | $17.04 | $37.51 |
| Resistance Level | $17.24 | $38.31 |
| Average True Range (ATR) | 0.26 | 1.59 |
| MACD | 0.02 | 0.40 |
| Stochastic Oscillator | 74.07 | 79.33 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.